Literature DB >> 10508045

Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing.

J Lipman1, S C Wallis, C Rickard.   

Abstract

The pharmacokinetics of a 2-g bolus of cefepime were measured in critically ill patients with normal renal function. Variable and low trough plasma drug concentrations were found, and 8 of 10 patients had levels below the MIC at which 50% of the isolates are inhibited for Pseudomonas aeruginosa. Computer simulations predicted that continuous infusion and shorter dosing intervals would increase trough levels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508045      PMCID: PMC89521          DOI: 10.1128/AAC.43.10.2559

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Subtleties of antibiotic dosages--do doses and intervals make a difference in the critically ill?

Authors:  J Lipman; H H Crewe-Brown; G L Saunders; A G Gous
Journal:  S Afr J Surg       Date:  1996-11       Impact factor: 0.375

2.  Intermittent bolus dosing of ceftazidime in critically ill patients.

Authors:  R J Young; J Lipman; T Gin; C D Gomersall; G M Joynt; T E Oh
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

3.  High-performance liquid chromatographic assay for cefepime in serum.

Authors:  H Elkhaïli; L Linger; H Monteil; F Jehl
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1997-03-07

4.  Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.

Authors:  W E Sanders; J H Tenney; R E Kessler
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

5.  Continuous infusion ceftazidime in intensive care: a randomized controlled trial.

Authors:  J Lipman; C D Gomersall; T Gin; G M Joynt; R J Young
Journal:  J Antimicrob Chemother       Date:  1999-02       Impact factor: 5.790

6.  Changes in vancomycin pharmacokinetics in critically ill infants.

Authors:  A G Gous; M D Dance; J Lipman; D K Luyt; R Mathivha; J Scribante
Journal:  Anaesth Intensive Care       Date:  1995-12       Impact factor: 1.669

7.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

8.  Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.

Authors:  B Fantin; R Farinotti; A Thabaut; C Carbon
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

Review 9.  Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  L B Barradell; H M Bryson
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

Review 10.  The pharmacodynamics of beta-lactams.

Authors:  J D Turnidge
Journal:  Clin Infect Dis       Date:  1998-07       Impact factor: 9.079

View more
  33 in total

Review 1.  Management of antimicrobial use in the intensive care unit.

Authors:  Francisco Álvarez-Lerma; Santiago Grau
Journal:  Drugs       Date:  2012-03-05       Impact factor: 9.546

Review 2.  Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness.

Authors:  Rina Mehrotra; Raffaele De Gaudio; Mark Palazzo
Journal:  Intensive Care Med       Date:  2004-11-05       Impact factor: 17.440

3.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.

Authors:  Mohammad H Al-Shaer; Michael N Neely; Jiajun Liu; Kartikeya Cherabuddi; Veena Venugopalan; Nathaniel J Rhodes; Kenneth Klinker; Marc H Scheetz; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 5.  Augmented renal clearance: implications for antibacterial dosing in the critically ill.

Authors:  Andrew A Udy; Jason A Roberts; Robert J Boots; David L Paterson; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

6.  High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.

Authors:  F Lamoth; T Buclin; A Pascual; S Vora; S Bolay; L A Decosterd; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

7.  Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Authors:  Anthony M Nicasio; Robert E Ariano; Sheryl A Zelenitsky; Aryun Kim; Jared L Crandon; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

Review 8.  Cefepime: a reappraisal in an era of increasing antimicrobial resistance.

Authors:  Andrea Endimiani; Federico Perez; Robert A Bonomo
Journal:  Expert Rev Anti Infect Ther       Date:  2008-12       Impact factor: 5.091

9.  Prospective monitoring of cefepime in intensive care unit adult patients.

Authors:  Thomas M Chapuis; Eric Giannoni; Paul A Majcherczyk; René Chioléro; Marie-Denise Schaller; Mette M Berger; Saskia Bolay; Laurent A Décosterd; Denis Bugnon; Philippe Moreillon
Journal:  Crit Care       Date:  2010-04-01       Impact factor: 9.097

10.  Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Thierry Dugernier; Herbert Spapen; Isabelle Delattre; Xavier Wittebole; Daniel De Backer; Brice Layeux; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-07-01       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.